Skip to main content
BusinessResearch

Isomorphic Labs raises $5 billion in its second mega-round within six months

Source: The Decoder (opens in a new tab) · Maximilian Schreiner

Intel Summary

Alphabet's AI drug discovery subsidiary, Isomorphic Labs, has raised $5 billion in a new funding round led by Demis Hassabis. Coming six months after a $2.1 billion raise, the capital is slated to advance the company's experimental drug pipeline toward clinical trials, though it currently has no approved drugs.

Why It Matters

The multi-billion-dollar influx highlights extreme capital concentration in AI-driven life sciences, reflecting the heavy financial runway required to validate computational biological models through regulated clinical trials.

Organizations & Entities

Topics